Search results
Results from the WOW.Com Content Network
Lithium-associated hyperparathyroidism is the leading cause of hypercalcemia in lithium-treated patients. Lithium may lead to exacerbation of pre-existing primary hyperparathyroidism or cause an increased set-point of calcium for parathyroid hormone suppression, leading to parathyroid hyperplasia.
Lithium toxicity, also known as lithium overdose, is the condition of having too much lithium. Symptoms may include a tremor, increased reflexes, trouble walking, kidney problems, and an altered level of consciousness .
Lithium Lithium is the "classic" mood stabilizer, the first to be approved by the US FDA, and still popular in treatment. Therapeutic drug monitoring is required to ensure lithium levels remain in the therapeutic range: 0.6 to 0.8 or 0.8–1.2 mEq/L (or millimolar).
Patient education is a planned interactive learning process designed to support and enable expert patients [1] to manage their life with a disease and/or optimise their health and well-being. [ 2 ] [ 3 ]
In 1948, lithium was first used as a psychiatric medicine. One of the most important discoveries was chlorpromazine , an antipsychotic that was first given to a patient in 1952. In the same decade, Julius Axelrod carried out research into the interaction of neurotransmitters, which provided a foundation for the development of further drugs. [ 9 ]
Irvin M. Cohen, M.D. (1922–2019) was a psychiatrist specializing in psychopharmacology, recognized for his role in the early use of chlorpromazine in the treatment of schizophrenia, the development of the first benzodiazepine [1] treatments in depressive patients, and in the adoption of lithium to treat bipolar disorder.
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Lithium has been used to augment antidepressant therapy in those who have failed to respond to antidepressants alone. [89] Furthermore, lithium dramatically decreases the suicide risk in recurrent depression. [90] According to the results of the STAR-D experiment, the remission rate of lithium for treatment-resistant depression is about 15.9%. [91]